These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24225007)

  • 21. [Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007 - an update].
    Porret E; Madelaine J; Galateau-Sallé F; Bergot E; Zalcman G
    Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S157-64. PubMed ID: 18235409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.
    Maehara S; Usuda J; Ishizumi T; Ichinose S; Ohtani K; Inoue T; Imai K; Furumoto H; Kudo Y; Kajiwara N; Ohira T; Ikeda N
    Int J Oncol; 2015 Feb; 46(2):741-9. PubMed ID: 25385189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current issues in malignant pleural mesothelioma evaluation and management.
    Ai J; Stevenson JP
    Oncologist; 2014 Sep; 19(9):975-84. PubMed ID: 25061089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
    Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
    Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
    Cihan YB; Ozturk A; Mutlu H
    Asian Pac J Cancer Prev; 2014; 15(5):2061-7. PubMed ID: 24716935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Standard therapy for the treatment of malignant pleural mesothelioma.
    Vogelzang NJ
    Lung Cancer; 2005 Oct; 50 Suppl 1():S23-4. PubMed ID: 16291429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
    Zauderer MG; Bott M; McMillan R; Sima CS; Rusch V; Krug LM; Ladanyi M
    J Thorac Oncol; 2013 Nov; 8(11):1430-3. PubMed ID: 24128712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pemetrexed in malignant pleural mesothelioma.
    Gatzemeier U
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):26-31. PubMed ID: 15655933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
    Jing XQ; Zhou L; Sun XD; Yu JM; Meng X
    Medicine (Baltimore); 2016 Apr; 95(14):e3351. PubMed ID: 27057918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Malignant pleural mesothelioma].
    Nishiwaki Y
    Gan To Kagaku Ryoho; 2003 May; 30(5):589-94. PubMed ID: 12795087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
    Fizazi K; John WJ; Vogelzang NJ
    Semin Oncol; 2002 Feb; 29(1):77-81. PubMed ID: 11836672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pemetrexed for diffuse malignant pleural mesothelioma.
    Manegold C; Aisner J
    Semin Oncol; 2002 Apr; 29(2 Suppl 5):30-5. PubMed ID: 12023790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second-line treatment for malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Gianoncelli L; Lorenzi E; Santoro A
    Cancer Treat Rev; 2010 Feb; 36(1):24-32. PubMed ID: 19879055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
    J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
    Ellis P; Davies AM; Evans WK; Haynes AE; Lloyd NS;
    J Thorac Oncol; 2006 Jul; 1(6):591-601. PubMed ID: 17409924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
    Taylor P; Castagneto B; Dark G; Marangolo M; Scagliotti GV; van Klaveren RJ; Labianca R; Serke M; Schuette W; van Meerbeeck JP; Heigener D; Liu Y; Adachi S; Blatter J; von Pawel J
    J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
    J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemetrexed-cisplatin combination in mesothelioma.
    Reck M; Gatzemeier U
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):231-7. PubMed ID: 15877521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
    Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
    Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deciduoid pleural mesothelioma in an adolescent.
    Arango-Tomás E; Algar-Algar FJ; Salvatierra Velázquez A
    Arch Bronconeumol; 2013 May; 49(5):218-9. PubMed ID: 23265622
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.